Extended indication Treatment of moderate to severe chronic pain in patients with opioid dependence.
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Buprenorphine
Domain Neurological disorders
Reason of inclusion Indication extension
Main indication Pain
Extended indication Treatment of moderate to severe chronic pain in patients with opioid dependence.
Proprietary name Buvidal
Manufacturer Camurus
Mechanism of action Receptor agonist
Route of administration Subcutaneous
Therapeutical formulation Injection
Budgetting framework Extramural (GVS)

Registration

Submission date November 2021
Expected Registration September 2022
Orphan drug No
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

References https://www.zorginstituutnederland.nl/publicaties/adviezen/2021/07/21/gvs-advies-subcutaan-buprenorfine-buvidal
Additional comments Er zijn 7 verschillende doseringen beschikbaar: 4 doseringen zijn geschikt voor de wekelijkse toediening en 3 doseringen zijn geschikt voor de maandelijkse toediening. De apotheekinkoopprijs (AIP) is voor alle wekelijkse doseringen gelijk, dit komt neer op €87. Voor alle maandelijkse doseringen komt de AIP uit op €375,88.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.